CLAIMS

What is claimed:

1. Use of 120 mg or 180 mg ETC-1002 and 2-80 mg of one or more statins selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin in the manufacture of a medicament for treating hypercholesterolemia in a subject in need thereof.

2. The use of claim 1, wherein the medicament decreases the level of total cholesterol and non-HDL-C in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

3. The use of claim 1, wherein the medicament decreases the level of low density lipoprotein (LDL) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

4. The use of claim 1, wherein the medicament decreases the number of LDL particles in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

5. The use of claim 1, wherein the medicament decreases the level of apolipoprotein B (ApoB) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

6. The use of claim 1, wherein the medicament decreases the level of apolipoprotein A-1 (ApoA1) in the subject below that of a control subject receiving placebo, a 120 mg

dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

7. The use of claim 1, wherein the medicament decreases the ratio of apolipoprotein B (ApoB) to apolipoprotein A-1 (ApoA1) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

8. The use of claim 1, wherein the subject has atherosclerotic cardiovascular disease.

9. The use of claim 1, wherein the subject has familial hypercholesterolemia.

10. The use of claim 1, wherein the subject is human.

11. A fixed-dose combination comprising a therapeutic amount of ETC-1002 and one or more statins selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin.

12. The fixed-dose combination of claim 11, wherein the amount of each of the one or more statins is 2-80 mg.

13. The fixed-dose combination of claim 11, wherein the amount of ETC-1002 is 120 mg or 180 mg and the amount of each of the one or more statins is 2-80 mg.

14. Use of 120 mg or 180 mg ETC-1002 and 2-80 mg of one ore more statins selected from the group consisting of rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, atorvastatin, and pitavastatin in the manufacture of a medicament for lowering low density lipoprotein-cholesterol (LDL-C) in a subject in need thereof.

15. The use of claim 14, wherein the subject has atherosclerotic cardiovascular disease.

16. The use of claim 14, wherein the subject has familial hypercholesterolemia.

17. The use of claim 14, wherein the medicament decreases the level of total cholesterol and non-HDL-C in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

18. The use of claim 14, wherein the medicament decreases the level of low density lipoprotein (LDL) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

19. The use of claim 14, wherein the medicament decreases the number of LDL particles in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

20. The use of claim 14, wherein the medicament decreases the level of apolipoprotein A-1 (ApoA1) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of the one or more statins.

21. The use of claim 14, wherein the medicament decreases the level of total cholesterol and non-HDL-C in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-80 mg dose of one or more statins.

22. The use of claim 14, wherein the medicament decreases the ratio of apolipoprotein B (ApoB) to apolipoprotein A-1 (ApoA1) in the subject below that of a control subject receiving placebo, a 120 mg dose of ETC-1002, a 180 mg dose of ETC-1002, or a 2-

80 mg dose of the one or more statins.

23. The use of any one of claims 1-10 and 14-22, wherein the amount of ETC-1002 is 120 mg.

24. The use of any one of claims 1-10, and 14-22, wherein the amount of ETC-1002 is 180 mg.

25. The use of claim 23, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

26. The use of claim 24, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

27. The use of claim 23, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg.

28. The use of claim 24, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg.

29. The use of claim 23, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

30. The use of claim 24, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

31. The use of claim 23, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

32. The use of claim 24, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

33. The use of claim 23, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

34. The use of claim 24, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

35. The use of claim 23, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

36. The use of claim 24, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

37. The use of claim 23, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.

38. The use of claim 24, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.

39. The fixed-dose combination of any one of claims 11-13, wherein the amount of ETC-1002 is 120 mg.

40. The fixed-dose combination of any one of claims 11-13, wherein the amount of ETC-1002 is 180 mg.

41. The fixed-dose combination of claim 39, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

42. The fixed-dose combination of claim 40, wherein the one or more statins is rosuvastatin; and the amount of rosuvastatin is 5-40 mg.

43. The fixed-dose combination of claim 39, wherein the one or more statins is

simvastatin; and the amount of simvastatin is 10-80 mg..

44. The fixed-dose combination of claim 40, wherein the one or more statins is simvastatin; and the amount of simvastatin is 10-80 mg.

45. The fixed-dose combination of claim 39, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

46. The fixed-dose combination of claim 40, wherein the one or more statins is pravastatin; and the amount of pravastatin is 10-80 mg.

47. The fixed-dose combination of claim 39, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

48. The fixed-dose combination of claim 40, wherein the one or more statins is lovastatin; and the amount of lovastatin is 20-40 mg.

49. The fixed-dose combination of claim 39, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

50. The fixed-dose combination of claim 40, wherein the one or more statins is fluvastatin; and the amount of fluvastatin is 20-80 mg.

51. The fixed-dose combination of claim 39, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

52. The fixed-dose combination of claim 40, wherein the one or more statins is pitavastatin; and the amount of pitavastatin is 1-4 mg.

53. The fixed-dose combination of claim 39, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.

54. The fixed-dose combination of claim 40, wherein the one or more statins is atorvastatin; and the amount of atorvastatin is 10-80 mg.